首页> 美国卫生研究院文献>British Heart Journal >Plasma and tissue digoxin concentrations in patients undergoing cardiopulmonary bypass.
【2h】

Plasma and tissue digoxin concentrations in patients undergoing cardiopulmonary bypass.

机译:进行体外循环的患者血浆和组织中地高辛的浓度。

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Plasma myocardial, and skeletal muscle digoxin concentrations were measured in 32 patients undergoing cardiopulmonary bypass who were on long-term treatment with digoxin. The patients were divided into 4 groups according to the daily digoxin dose and the interval between discontinuation of the drug and operation. Before bypass, the mean digoxin concentrations were 1.58 nmol/l (1.24 ng/ml) in plasma 65.2 nmol/kg (50.9 ng/g) in the atria, 121.4 nmol/kg (94.98 ng/g) in 11 papillary muscles, and 16.6 nmol/kg (13.0 ng/g) in skeletal muscle. Mean atrial digoxin concentrations were significantly lower tham mean papillary muscle concentrations in 11 patients. Ratios of plasma of myocardial or skeletal muscle digoxin concentrations were very variable. Generally digoxin concentrations were higher in patients on the larger digoxin dose and with the shorter discontinuation time before surgery. These differences attained significance only with plasma digoxin concentrations. There was a slight fall in plasma digoxin concentration during cardiopulmonary bypass but no significant differences were observed between plasma, atrial, or skeletal muscle digoxin concentrations before and at the end of bypass. No clear relation was seen between plasma or atrial digoxin concentrations and postoperative cardiotoxicity. Stopping digoxin 48 hours before operation appeared to account for pre- or post-bypass plasma digoxin concentrations of less than 1.0 nmol/l (0.8 ng/ml) in most of the instances encountered, whereas the 3 patients who developed pulsus bigeminus postoperatively had received 0.5 mg digoxin only 24 hours before operation.
机译:在长期接受地高辛治疗的32例行体外循环的患者中,测定了血浆心肌和骨骼肌地高辛的浓度。根据地高辛的每日剂量以及停药和手术之间的间隔将患者分为4组。在绕过之前,心房血浆中地高辛的平均浓度为1.58 nmol / l(1.24 ng / ml),心房血浆中的平均地高辛浓度为65.2 nmol / kg(50.9 ng / g),11根乳头肌中为121.4 nmol / kg(94.98 ng / g),骨骼肌中的16.6 nmol / kg(13.0 ng / g)。心房地高辛的平均浓度显着低于11例患者的平均乳头肌浓度。血浆中心肌或骨骼肌地高辛浓度的比率变化很大。通常,随着地高辛剂量的增加和手术前停药时间的缩短,患者地高辛的浓度会更高。这些差异仅在血浆地高辛浓度下才有意义。在体外循环期间,血浆地高辛浓度略有下降,但在旁路前和结束时血浆,心房或骨骼肌中地高辛浓度之间未观察到显着差异。血浆或心房地高辛浓度与术后心脏毒性之间没有明确的关系。术前48小时停止使用地高辛似乎是造成大多数情况下旁路前或旁路后血浆地高辛浓度低于1.0 nmol / l(0.8 ng / ml)的原因,而3例术后出现大搏动的患者已接受术前24小时仅服用0.5 mg地高辛。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号